NIRAVAM
Clinical safety rating: caution
Comprehensive clinical and safety monograph for NIRAVAM (NIRAVAM).
NIRAVAM (alprazolam) is a benzodiazepine that potentiates GABA-A receptor activity by increasing the frequency of chloride channel opening, leading to neuronal hyperpolarization and decreased excitability.
| Metabolism | Primarily hepatic via CYP3A4; major metabolites include alpha-hydroxyalprazolam (active) and 4-hydroxyalprazolam (inactive), both conjugated and excreted renally. |
| Excretion | Renal: ~90% as metabolites (glucuronide conjugates and oxidized products), <5% unchanged. Fecal: <10%. |
| Half-life | Terminal elimination half-life: 8–14 hours (mean 10.5 h). Clinically, steady-state reached in ~3 days; accumulation minimal at typical dosing. |
| Protein binding | ~95% bound, primarily to albumin. |
| Volume of Distribution | 1.5–2.5 L/kg (mean 1.8 L/kg). Indicates extensive tissue distribution including CNS. |
| Bioavailability | Sublingual: ~75% (avoiding first-pass). Oral: ~50% (due to first-pass metabolism). |
| Onset of Action | Sublingual: 15–30 minutes (faster absorption vs oral, due to bypass of first-pass metabolism). Oral: 30–60 minutes. |
| Duration of Action | Sublingual: 4–6 hours (anxiolytic effect). Oral: 6–8 hours. Duration correlates with half-life; shorter than other benzodiazepines. |
| Molecular Weight | 281.27 |
0.25–0.5 mg sublingually every 6–8 hours as needed; maximum 2 mg/day.
| Dosage form | TABLET, ORALLY DISINTEGRATING |
| Renal impairment | No specific guidelines; use cautiously in severe impairment (CrCl <30 mL/min) due to potential accumulation. |
| Liver impairment | Child-Pugh Class A: no adjustment; Child-Pugh Class B: 0.25 mg every 8–12 hours; Child-Pugh Class C: not recommended. |
| Pediatric use | Not FDA-approved for pediatric use; no established weight-based dosing. |
| Geriatric use | Initial dose 0.25 mg sublingually every 8–12 hours; increase cautiously. Avoid use in elderly with hepatic impairment or renal impairment. |
| 1st trimester | Risk of congenital malformations, particularly cleft lip/palate, with first trimester benzodiazepine exposure. Associated with floppy infant syndrome and withdrawal symptoms in neonates after late pregnancy exposure. |
| 2nd trimester | Similar risks as T1; use only if benefit outweighs risk. May cause fetal growth restriction. |
| 3rd trimester | Avoid in third trimester due to risk of neonatal respiratory depression, hypotonia, withdrawal, and floppy infant syndrome. |
Clinical note
Comprehensive clinical and safety monograph for NIRAVAM (NIRAVAM).
| Placental transfer | Nitrazepam crosses the placenta readily, similar to other benzodiazepines. Fetal concentrations can approach maternal levels. |
| Breastfeeding | Nitrazepam (Niravam) is excreted into breast milk in low concentrations. Sedation, poor feeding, and weight loss have been reported in infants. Monitor for drowsiness and feeding difficulties. Consider alternative agents with lower milk transfer. |
■ FDA Black Box Warning
Risk of serious adverse outcomes from concomitant use with opioid medications, including respiratory depression, profound sedation, coma, and death. Reserve use for patients with inadequate alternative treatment options.
| Serious Effects |
Hypersensitivity to nitrazepam or any benzodiazepineSevere hepatic impairmentAcute narrow-angle glaucomaMyasthenia gravisSevere respiratory insufficiencySleep apnea syndrome
| Precautions | Risk of abuse, misuse, and addiction; dependence and withdrawal reactions; risk of CNS depression and impaired psychomotor function; caution in patients with hepatic impairment, renal impairment, or respiratory disease; risk of paradoxical reactions; potential for neonatal sedation and withdrawal syndrome when used during pregnancy. |
| Food/Dietary | Grapefruit and grapefruit juice may increase alprazolam levels; avoid concurrent use. No other significant food restrictions; take with or without food. |
Loading safety data…
| Lactation Rating | L3 (Moderately Safe) - Limited data suggest risk; use with caution and monitor infant. |
| Teratogenic Risk | FDA Pregnancy Category D. First trimester: case reports of cleft lip/palate (odds ratio ~2.0). Second and third trimesters: risk of floppy infant syndrome, neonatal withdrawal (hypertonia, tremors, feeding difficulties), and respiratory depression. Use only if benefit outweighs risk. |
| Fetal Monitoring | Monitor maternal sedation, respiratory rate, and withdrawal symptoms. Fetal ultrasound for growth and anomalies if used in first trimester. Neonatal monitoring for respiratory depression, floppy infant syndrome, and withdrawal for 48-72 hours postpartum. |
| Fertility Effects | No human data on fertility impairment. In animal studies, no adverse effects on fertility at clinically relevant doses. Theoretical risk of menstrual cycle disruption due to CNS depression. |
| Clinical Pearls | NIRAVAM (alprazolam orally disintegrating tablet) has a faster onset than regular alprazolam tablets; instruct patients to not swallow tablet whole but to place on tongue. Avoid in narrow-angle glaucoma, severe hepatic impairment, or concurrent use of strong CYP3A4 inhibitors like ketoconazole. |
| Patient Advice | Take NIRAVAM by placing the tablet on your tongue where it will dissolve quickly; do not swallow the tablet whole. · Avoid alcohol and other CNS depressants while taking this medication. · Do not stop taking NIRAVAM abruptly as withdrawal seizures may occur; taper under medical supervision. · Notify your doctor if you are pregnant, breastfeeding, or have a history of substance abuse. · This drug may cause drowsiness or dizziness; avoid driving or operating heavy machinery until you know how it affects you. |